128 related articles for article (PubMed ID: 7807185)
21. Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin.
Lustgarten J; Waks T; Eshhar Z
Mol Immunol; 1996 Feb; 33(3):245-51. PubMed ID: 8649445
[TBL] [Abstract][Full Text] [Related]
22. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
[TBL] [Abstract][Full Text] [Related]
23. Mouse L1210V leukemia as a model to analyse efficiency of leukemic cell elimination by immunotoxin, antibody and complement, and cytostatic agents.
Paprocka M; Wiedlocha A; Radzikowski C
In Vivo; 1990; 4(3):209-13. PubMed ID: 2133264
[TBL] [Abstract][Full Text] [Related]
24. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
25. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.
Hertler AA; Schlossman DM; Borowitz MJ; Poplack DG; Frankel AE
Cancer Immunol Immunother; 1989; 28(1):59-66. PubMed ID: 2783301
[TBL] [Abstract][Full Text] [Related]
26. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
Spitler LE; Mischak R; Scannon P
Int J Rad Appl Instrum B; 1989; 16(6):625-7. PubMed ID: 2606718
[No Abstract] [Full Text] [Related]
27. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
[TBL] [Abstract][Full Text] [Related]
29. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody immunoconjugates in the diagnosis and treatment of advanced melanoma.
Bhardwaj S
Mt Sinai J Med; 1992 May; 59(3):207-10. PubMed ID: 1603109
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
Zangemeister-Wittke U; Collinson AR; Fisch I; Jones RM; Waibel R; Lehman HP; Stahel RA
Int J Cancer; 1993 Jul; 54(6):1028-35. PubMed ID: 8392978
[TBL] [Abstract][Full Text] [Related]
34. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
35. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
[TBL] [Abstract][Full Text] [Related]
37. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
[TBL] [Abstract][Full Text] [Related]
38. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
40. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies.
Griffin TW; Stocl M; Collins J; Fernandes J; Maher VE
J Immunother (1991); 1992 Jan; 11(1):12-8. PubMed ID: 1734944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
